PULMONARY EMPHYSEMA

THE RATIONALE FOR

THERAPEUTIC INTERVENTION

Edited by George Weinbaum, Ralph E. Giles, and Robert D. Krell

The New York Academy of Sciences
New York, New York
1991
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES

Volume 624
May 22, 1991

PULMONARY EMPHYSEMA
THE RATIONALE FOR THERAPEUTIC INTERVENTION

Editors
GEORGE WEINBAUM, RALPH E. GILES, AND ROBERT D. KRELL

Conference Organizers
ROBERT D. KRELL, GEORGE WEINBAUM, AND RALPH E. GILES

CONTENTS

Preface. By GEORGE WEINBAUM, ROBERT D. KRELL, AND RALPH E. GILES .................................................. xi

Part 1. Epidemiology, Risk Factors, and Approaches to Therapy

Emphysema Before and After 1963. Historical Perspectives. By STEN ERIKSSON ..................................................... 1

Risk Factors Associated with Chronic Obstructive Lung Disease. By MILICENT HIGGINS .......................... 7

Natural History and Clinical Management of Emphysema in Patients with and without Alpha,-Antitrypsin Inhibitor Deficiency. By GERARD M. TURINO ....................................................... 18


Nonsteroidal Antiinflammatory Drugs. By STEVEN B. ABRAMSON ........ 40

Part 2. Putative Etiologies of Emphysema: Proteases/Inhibitors/Modulators

Putative Role of Neutrophil Elastase in the Pathogenesis of Emphysema. By GORDON L. SNIDER, DAVID E. CICCOLELLA, SHIRLEY M. MORRIS, PHILLIP J. STONE, AND EDGAR C. LUCEY ..................... 45

This volume is the result of a conference entitled Pulmonary Emphysema: The Rationale for Therapeutic Intervention, which was sponsored by the New York Academy of Sciences and the American Thoracic Society and held on May 16–18, 1990 in Lake Buena Vista, Florida.
Proteinase-3 (PR-3): A Polymorphonuclear Leukocyte Serine Proteinase. By N. V. Rao, Nancy G. Wehner, Bruce C. Marshall, Anne B. Sturrock, Thomas P. Huecksteadt, Gopna V. Rao, Beulah H. Gray, and John R. Hoidal ........................................... 60

Elastin Degradation by Mononuclear Phagocytes. By Steven D. Shapiro, Edward J. Campbell, Howard G. Welgus, and Robert M. Senior ................................................................. 69

Neutrophil Proteinases. Caution Signs in Designing Inhibitors Against Enzymes with Possible Multiple Functions. By James Travis, Adam Dubin, Jan Potempa, Wieslaw Watorek, and Anna Kurdowska ............................................................... 81

Role of Enzyme Receptors and Inhibitors in Regulating Proteolytic Activities of Macrophages. By Harold A. Chapman, Jr. .................... 87


Secreted Inhibitors of Mammalian Metalloproteinases. By Michael J. Banda and Eric W. Howard .................................................. 109

Regulation of Elastin Gene Expression. By Joel Rosenbloom, Muhammad Bashir, Helena Yeh, Joan Rosenbloom, Norma Ornstein-Goldstein, Michael Fazio, Veli-Matti Kahari, and Jouni Uitto ......................................................... 116

Elastin Synthesis and Fiber Assembly. By Robert P. Meacham .......... 137

Part 3. New Approaches to the Monitoring of Emphysema


Development and Application of Assays for Elastase-Specific Fibrinogen Fragments. By Jeffrey I. Weitz ........................................... 154


Quantifying Emphysema by CT Scanning. Clinicopathologic Correlates. By William MacNee, Graham Gould, and David Lamb .......... 179

The Feasibility of an Outcome Trial in the Preventive Therapy of Emphysema. By Mitchell Glass ............................................... 195

Part 4. The Present: Approaches to Emphysema Therapy

Lung Transplantation for Chronic Obstructive Lung Disease. By Joel D. Cooper .......................................................... 209
Recombinant Elastase Inhibitors for Therapy. By Hans Peter Schnebli. 212
Biochemistry and Pharmacology of ICI 200,880, a Synthetic Peptide Inhibitor of Human Neutrophil Elastase. By Joseph C. Williams, Ross L. Stein, Ralph E. Giles, and Robert D. Krell .............. 230
Reduction of Neutrophil Elastase Load in the Lungs of Patients with Emphysema by Reducing Neutrophil Enzyme Secretion or Chemotaxis. By Allen B. Cohen, William Girard, Jerry McLarty, Barry Starcher, Doris Davis, Michael Stevens, Joel Rosenbloom, and Umberto Kucich ..................... 244

Part 5. The Future: Potential Involvement of Proteases in Pulmonary Pathology Other Than Emphysema
Proteinases in Chronic Lung Infection. By R. A. Stockley, S. L. Hill, and D. Burnett .......................... 257
Protease Mechanisms in the Pathogenesis of Acute Lung Injury. By Thomas L. Petty ...................... 267
Protease Actions on Airway Secretions. Relevance to Cystic Fibrosis. By Jay A. Nadel ......................... 286
Potential Role of Proteases in Pulmonary Fibrosis. By Moisés Selman and Annie Pardo ..................... 297

Part 6. Poster Papers
Contribution of Additional Elastase Inhibitors Other Than Alpha1-Protease Inhibitor and Bronchial Antileukoprotease to Neutrophil Elastase Inhibiting Capacity of Bronchoalveolar Lavage. By Raja Abboud, Angus Tsang, and Marta Taller ............ 315
Eglin C and Heparin Inhibition of Platelet Activation Induced by Cathepsin G or Human Neutrophils. By P. REINSTO, P. FERRER-LOPEZ, AND M. CHIGNARD ........................................... 321

Does Cigarette Smoke Enhance the Proteolytic Activity of Neutrophils? By K. DONALDSON, G. M. BROWN, E. DROST, C. SELBY, AND W. MACNEE ............................... 325

Bronchial Inhibitor in Human Lung. By B. FOX, T. B. BULL, A. GULZ, AND T. D. TETLEY ................................................................. 328


Pulmonary Hemorrhage Induced by Intratracheal Administration of Human Leukocyte Elastase in Hamsters. By ROBERT J. GORDON, EDWARD FERGUSON, RICHARD DUNLAP, CATHERINE FRANKE, AND PAUL J. SILVER ...................................................... 331

Purification of Elastin Antigen(s) from the Urine of Patients with Emphysema. By U. KUCICH, J. HAMILTON, S. AKERS, P. KIMBEL, S. METTE, J. ROSENBLUM, AND G. WEINBAUM ............................................ 334

Relationship between Intraalveolar Macrophage Population and Microscopic Emphysema. By D. LAMB, A. MCLEAN, AND W. WALLACE .......................................................... 337

Microscopic Emphysema and Its Variations with Age, Smoking, and Site within the Lungs. By D. LAMB, M. GILLOOLY, AND A. S. J. FARROW .................................................................. 339

A Polymer-Bound Elastase Inhibitor Is Effective in Preventing Human Neutrophil Elastase-Induced Emphysema. By E. C. LUCEY, P. J. STONE, G. A. DIGENIS, AND G. L. SNIDER ................................................................. 341

On the Activity of MR 889, a New Synthetic Proteinase Inhibitor. By M. LUISETTI, P. D. PICCIIONI, M. DONNINI, R. ALESINA, A. M. DONNETTA, AND V. PEONA .................................................. 343

Development of Cor Pulmonale in Tight-Skin Mice with Genetic Emphysema. By P. A. MARTORANA, M. WILKINSON, M. M. DE SANTI, P. VAN EVEN, C. GARDI, AND G. LUNGARELLA ........................................... 345


Lipopolysaccharide-Induced Alveolar Wall Destruction in the Hamster Is Inhibited by Intratracheal Treatment with r-Secretory Leukocyte Protease Inhibitor. By J. STOLK, A. RUDOLPHUS, AND J. A. KRAMPS .......... 350

Neutrophil Traffic Through the Lungs in Man. By C. SELBY, E. DROST, P. K. WRAITH, AND W. MACNEE .......................................................... 353


Ten-Year Changes of Protease Inhibitors in the Sons of Patients with COPD. By A. Yoshioka, H. Nagata, M. Yamamoto, Y. Akiyama, M. Nishimura, K. Miyamoto, F. Kishi, and Y. Kawakami .................................................. 359

Early Diagnosis of Pulmonary Emphysema in Smokers. By Jaime W. Fidalgo-Garrido and José L. Martinez-Carrasco .......... 362

Rapid Screening for Human Alpha 1-Proteinase Inhibitor Deficiency. By C. A. Lloyd and K. D. Arbtan ................. 365

Index of Contributors .................................................. 369